Related Experiment Video

Updated: Aug 14, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

CRIPak, a novel endogenous Pak1 inhibitor

A H Talukder1, Q Meng, R Kumar

  • 1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Oncogene
|November 10, 2005
PubMed

Insights

Cysteine-rich inhibitor of Pak1 (CRIPak) is a newly discovered protein that negatively regulates p21-activated protein kinase 1 (Pak1). CRIPak inhibits Pak1 activity, impacting cell survival and estrogen receptor signaling in breast cancer.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • p21-activated protein kinase 1 (Pak1) is crucial for cell functions like cytoskeleton reorganization, cell survival, and estrogen receptor (ER) signaling.
  • Deregulation of Pak1 is observed in various cancers, highlighting the need to understand its regulatory mechanisms.
  • While Pak1 activators are known, negative regulators remain less understood.

Purpose of the Study:

  • To identify and characterize novel negative regulators of Pak1.
  • To investigate the interaction between CRIPak and Pak1.
  • To determine the functional role of CRIPak in Pak1-mediated cellular processes, particularly ER transactivation.

Main Methods:

  • Yeast two-hybrid screening of a mammary gland library to identify Pak1-interacting proteins.
  • Gene localization and domain analysis of the identified protein.
  • In vitro and in vivo kinase assays to assess Pak1 inhibition by CRIPak.
  • Analysis of Pak1-mediated LIM kinase activation and ER transactivation.
  • CRIPak inhibition studies to observe effects on Pak1 activity and cellular processes.
  • Immunofluorescence to study CRIPak and ER colocalization.

Main Results:

  • Cysteine-rich inhibitor of Pak1 (CRIPak) was identified as a novel Pak1-interacting protein.
  • CRIPak, an intronless gene on chromosome 4p16.3, contains zinc-finger and cysteine-rich domains and is widely expressed.
  • CRIPak directly binds to the N-terminal regulatory domain of Pak1 and inhibits its kinase activity.
  • CRIPak suppresses Pak1-mediated LIM kinase activation and ER transactivation.
  • Inhibition of endogenous CRIPak leads to increased Pak1 activity, cytoskeleton remodeling, and ER transactivation.
  • Hormonal stimulation increases CRIPak expression and its nuclear colocalization with ER.

Conclusions:

  • CRIPak is a novel negative regulator of Pak1 kinase activity.
  • CRIPak plays a significant role in modulating Pak1-mediated ER transactivation in breast cancer cells.
  • CRIPak represents a potential therapeutic target for cancers involving Pak1 dysregulation.

More Related Videos

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...